Officials with two pharmaceutical companies who produce monoclonal antibody treatments said Wednesday that the U.S. government distributes the currently-available supply of those treatments and that those companies may not sell them to hospitals or state governments. A spokesman for the New York state-based Regeneron, who identified himself only as Alex, said the U.S. government owns the currently available supply of REGEN-COV, which is the company’s monoclonal antibody treatment. The U.S. government allocates that product to state governments.
Read MoreTwo Big Pharmaceutical Companies Sell Monoclonal Antibodies to Federal Government Only, Refuse to Sell to Hospitals or States
